Andrew Forman Christian Lorenz

May 01, 2015 | Corporate Counsel

Developing an efficient strategy to deal with the Federal Trade Commission and other antitrust agencies reviewing pharmaceutical transactions has never been more important for companies.

By Andrew Forman, Christian Lorenz and Evan Harris

6 minute read

May 01, 2015 | Corporate Counsel

Developing an efficient strategy to deal with the Federal Trade Commission and other antitrust agencies reviewing pharmaceutical transactions has never been more important for companies.

By Andrew Forman, Christian Lorenz and Evan Harris

6 minute read